1. ホーム
  2. 一覧
論文 特許

論文 - 一覧

  • 13 Hits
  • 検索条件 : 絞込み (MeSH = Antibodies, Monoclonal, Humanized)
生物種 リソース名 タイトル
ヒト・動物細胞 EBC-1(RCB1965) , KP4(RCB1005) Preclinical Profile of BYON3521 Predicts an Effective and Safe MET Antibody-Drug Conjugate.
ヒト・動物細胞 PC-9(RCB4455) Lack of AKT activation in lung cancer cells with EGFR mutation is a novel marker of cetuximab sensitivity.
ヒト・動物細胞 K562(RCB0027) Calicheamicin-conjugated humanized anti-CD33 monoclonal antibody (gemtuzumab zogamicin, CMA-676) shows cytocidal effect on CD33-positive leukemia cell lines, but is inactive on P-glycoprotein-expressing sublines.
ヒト・動物細胞 MKN1(RCB1003) Suppression of tumor growth in human gastric cancer with HER2 overexpression by an anti-HER2 antibody in a murine model.
ヒト・動物細胞 MKN1(RCB1003) Monitoring the cytoskeletal EGF response in live gastric carcinoma cells.
ヒト・動物細胞 Combining cetuximab with killer lymphocytes synergistically inhibits human cholangiocarcinoma cells in vitro.
ヒト・動物細胞 MKN1(RCB1003) , LMSU(RCB1062) Association of amphiregulin with the cetuximab sensitivity of gastric cancer cell lines.
ヒト・動物細胞 MRC-5 Hepatocyte growth factor induces resistance to anti-epidermal growth factor receptor antibody in lung cancer.
ヒト・動物細胞 MKN28(RCB1000) , MKN45(RCB1001) Interleukin-2 potentiation of cetuximab antitumor activity for epidermal growth factor receptor-overexpressing gastric cancer xenografts through antibody-dependent cellular cytotoxicity.
ヒト・動物細胞 Antibody-dependent cellular cytotoxicity mediated by cetuximab against lung cancer cell lines.
ヒト・動物細胞 K562 , Jurkat(RCB0806) CMC-544 (inotuzumab ozogamicin) shows less effect on multidrug resistant cells: analyses in cell lines and cells from patients with B-cell chronic lymphocytic leukaemia and lymphoma.
ヒト・動物細胞 K562(RCB0027) , Jurkat(RCB0806) CMC-544 (inotuzumab ozogamicin), an anti-CD22 immuno-conjugate of calicheamicin, alters the levels of target molecules of malignant B-cells.
ヒト・動物細胞 EBC-1(RCB1965) , Sq-1(RCB1905) , RERF-LC-AI(RCB0444) Anti-HER3 monoclonal antibody patritumab sensitizes refractory non-small cell lung cancer to the epidermal growth factor receptor inhibitor erlotinib.